Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome
Open Access
Abstract
BACKGROUND.: Cleavage of membrane‐anchored heparin‐binding epidermal growth factor‐like growth factor (proHB‐EGF) yields a soluble HB‐EGF isoform (sHB‐EGF), which is an activating epidermal growth factor receptor (EGFR) ligand and a C‐terminal fragment HB‐EGF‐C acting directly in the nucleus. In bladder cancer, overexpression of both HB‐EGF and EGFR have been observed, but to the authors' knowledge the prognostic significance of different modes of HB‐EGF signaling have remained unclear.METHODS.: Expression and intracellular localization of HB‐EGF and EGFR were examined by immunohistochemistry in paraffin‐embedded specimens from 121 patients who underwent cystectomy for bladder cancer. Tumor stage was pTis/pT1 in 7 patients, pT2 in 41 patients, pT3 in 55 patients, and pT4 in 18 patients. Lymph node metastases were present in 32 patients.RESULTS.: Using an antibody directed against the C‐terminal domain, HB‐EGF expression was detected in the cytoplasm or in the nucleus of tumor cells. EGFR staining was uniform at the plasma membrane. The actuarial 5‐year cancer‐specific survival of patients with tumors with predominant nuclear HB‐EGF staining was 28% compared with 57% if HB‐EGF staining was predominantly cytoplasmic (P = .027). Disease outcome of patients with a ‘mixed’ HB‐EGF staining pattern was found to be between that of the 2 former groups. In agreement with previous studies, strong EGFR expression was associated with poor prognosis. Despite strong EGFR expression, predominant cytoplasmic HB‐EGF staining was associated with a more favorable outcome, whereas a predominant nuclear pattern defined a subgroup with extremely poor prognosis (5‐year tumor‐specific survival of 55% vs 13%, respectively; P = .026).CONCLUSIONS.: The current study results confirm that EGFR expression is significantly correlated with disease‐specific mortality but that the outcome is also influenced by the mode of HB‐EGF signaling. Additional nuclear HB‐EGF signaling, indicative of increased cleavage of proHB‐EGF, appears to enhance the adverse activities. Cytoplasmic HB‐EGF staining likely reflects proHB‐EGF, which may also exert antiproliferative effects. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapyCancer Science, 2006
- Trafficking of Nuclear Heparin-Binding Epidermal Growth Factor–like Growth Factor into an Epidermal Growth Factor Receptor–Dependent Autocrine Loop in Response to Oxidative StressCancer Research, 2005
- Ectodomain shedding of membrane‐anchored heparin‐binding EGF like growth factor and subcellular localization of the C‐terminal fragment in the cell cycleJournal of Cellular Physiology, 2004
- Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer TherapyCancer Research, 2004
- Membrane-associated HB-EGF modulates HGF-induced cellular responses in MDCK cellsJournal of Cell Science, 2004
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF)Journal of Cellular Physiology, 2002
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001
- Contact-dependent Growth Inhibition and Apoptosis of Epidermal Growth Factor (EGF) Receptor-expressing Cells by the Membrane-anchored Form of Heparin-binding EGF-like Growth FactorJournal of Biological Chemistry, 1999
- Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cellsCancer Letters, 1996